ATE422556T1 - Hdac4- und hdac5-abhängige regulation der genexpression im herzen - Google Patents

Hdac4- und hdac5-abhängige regulation der genexpression im herzen

Info

Publication number
ATE422556T1
ATE422556T1 AT00955805T AT00955805T ATE422556T1 AT E422556 T1 ATE422556 T1 AT E422556T1 AT 00955805 T AT00955805 T AT 00955805T AT 00955805 T AT00955805 T AT 00955805T AT E422556 T1 ATE422556 T1 AT E422556T1
Authority
AT
Austria
Prior art keywords
cardiac hypertrophy
present
hdac5
hdac4
heart
Prior art date
Application number
AT00955805T
Other languages
English (en)
Inventor
Eric Olson
Jianrong Lu
Timothy Mckinsey
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE422556T1 publication Critical patent/ATE422556T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT00955805T 1999-08-20 2000-08-21 Hdac4- und hdac5-abhängige regulation der genexpression im herzen ATE422556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15004899P 1999-08-20 1999-08-20

Publications (1)

Publication Number Publication Date
ATE422556T1 true ATE422556T1 (de) 2009-02-15

Family

ID=22532889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955805T ATE422556T1 (de) 1999-08-20 2000-08-21 Hdac4- und hdac5-abhängige regulation der genexpression im herzen

Country Status (8)

Country Link
US (3) US6632628B1 (de)
EP (1) EP1210453B1 (de)
JP (1) JP2003507076A (de)
AT (1) ATE422556T1 (de)
AU (1) AU6794700A (de)
CA (1) CA2382045A1 (de)
DE (1) DE60041542D1 (de)
WO (1) WO2001014581A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350086A1 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
US6632628B1 (en) * 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
JP2001149081A (ja) * 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
WO2003025205A2 (en) * 2001-09-19 2003-03-27 Medigene Ag Extracellular regulated kinase 2 (erk2)
EP1605262A1 (de) * 2001-09-27 2005-12-14 Board Of Regents The University Of Texas System Methode zur Idenfitikation von Inhibitoren der Herzhypertrophie
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20030186289A1 (en) * 2002-01-22 2003-10-02 Myogen, Inc. Model cell systems for screening of anti-hypertrophic therapeutics
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040077083A1 (en) * 2002-10-17 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of histone deacetylase 4 expression
EP1608628A2 (de) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
US20060234245A1 (en) * 2003-08-29 2006-10-19 The Cleveland Clinic Foundation Pathogenic gene for coronary artery disease
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
CA2560334A1 (en) 2004-04-07 2005-10-20 Axiogenesis Ag Non-invasive, in vitro functional tissue assay systems
CA2565858C (en) 2004-05-11 2021-06-22 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
FI20040675A0 (fi) * 2004-05-12 2004-05-12 Orion Corp Menetelmä sydämen hypertrofian hoitoon ja estoon
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
AU2007281261B2 (en) * 2006-08-01 2013-03-21 Board Of Regents Of The University Of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
US20100212036A1 (en) * 2008-09-30 2010-08-19 Olson Eric N Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
WO2012009447A2 (en) * 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
WO2012155070A1 (en) * 2011-05-12 2012-11-15 Salk Institute For Biological Studies Modulation of lipid homeostatis, methods and compositions related thereto
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
EP3470536A1 (de) 2013-10-01 2019-04-17 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren zum wirkstoffscreening auf genexpressionsrauschen und verwendungen davon

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4668621A (en) 1985-04-22 1987-05-26 Wake Forest University Detecting blood clotting factors with immobilized fibrinogen and labeled fibrinogen
EP0273085A1 (de) 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US4843867A (en) * 1987-12-30 1989-07-04 American Sterilizer Company System for monitoring sterilant vapor concentration
JP3242916B2 (ja) 1990-12-14 2001-12-25 セル ジェネシス，インコーポレイティド レセプター関連シグナル変換系のためのキメラ鎖
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1994005776A1 (en) 1992-09-04 1994-03-17 The Children's Medical Center Corporation Myocyte-specific transcription enhancing factor 2
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5612455A (en) 1994-07-05 1997-03-18 Tularik, Inc. Nuclear factors and binding assay
US5600142A (en) * 1995-05-26 1997-02-04 Uop Measurement of vaporized hydrogen peroxide
US5872359A (en) * 1995-07-27 1999-02-16 American Sterilizer Company Real-time monitor and control system and method for hydrogen peroxide vapor decontamination
US5892229A (en) * 1996-04-22 1999-04-06 Rosemount Analytical Inc. Method and apparatus for measuring vaporous hydrogen peroxide
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
AU753047B2 (en) * 1997-11-14 2002-10-03 Ethicon Inc. Method for measuring the concentration of hydrogen peroxide vapor
US6632628B1 (en) * 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
US6451272B1 (en) * 1999-12-21 2002-09-17 Ethicon, Inc. Monitoring of sterilant apparatus and method for monitoring sterilant
US6875399B2 (en) * 2001-05-11 2005-04-05 Steris Inc. Non-dispersive mid-infrared sensor for vaporized hydrogen peroxide
ES2250673T3 (es) * 2001-07-10 2006-04-16 Steris Inc. Seguimiento y control por espectroscopia de infrarrojo medio para las tecnicas de procesamiento con vapor de peroxido de hidrogeno.
US6847393B2 (en) * 2002-04-19 2005-01-25 Wren Technology Group Method and system for monitoring point of sale exceptions
US6933733B2 (en) * 2003-03-14 2005-08-23 Steris Inc. Method and apparatus for measuring the concentration of hydrogen peroxide in a fluid
US6946852B2 (en) * 2003-03-14 2005-09-20 Steris Inc. Method and apparatus for measuring concentration of a chemical component in a gas mixture
US6953549B2 (en) * 2003-07-15 2005-10-11 Steris Inc. System and method for determining concentration of sterilant

Also Published As

Publication number Publication date
AU6794700A (en) 2001-03-19
US6632628B1 (en) 2003-10-14
US7420100B2 (en) 2008-09-02
EP1210453B1 (de) 2009-02-11
JP2003507076A (ja) 2003-02-25
EP1210453A2 (de) 2002-06-05
CA2382045A1 (en) 2001-03-01
US20050106654A1 (en) 2005-05-19
WO2001014581A2 (en) 2001-03-01
DE60041542D1 (de) 2009-03-26
WO2001014581A3 (en) 2001-09-20
US20090087412A1 (en) 2009-04-02
WO2001014581A9 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ATE422556T1 (de) Hdac4- und hdac5-abhängige regulation der genexpression im herzen
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
EA200500856A1 (ru) Новые химические соединения
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
ATE279959T1 (de) System zur regelung des herzrhythmus mit auswahl der elektroden
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DE69715861D1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MD970253A (ro) Inhibitori biciclici micromoleculari ai trombinei
DE69735442D1 (de) Antidiabetische mittel
EA200200390A1 (ru) Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
WO2000028020A3 (en) Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
ATE292976T1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
PT888327E (pt) Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos
EA199600078A1 (ru) Новый хелатообразователь железа как ингибитор процесса окисления, опосредованного железом
ATE347606T1 (de) Gentherapie für kongestives herzversagen
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
GB2346146A (en) Calcineurin-dependent control of skeletal muscle fiber type
BE899422A (fr) Diphenylazomethines substituees, leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties